General Information:

Id: 2,046 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Mus musculus
genetically diabetic C57BL/KSJ db/db mouse
BTO:0000991 pancreatic islet
Reference: Cheng Q et al.(2008) Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2-(1H-tetrazol-5-yl)-[1,1-biphenyl]-4-yl]methyl]-L-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes. J. Pharmacol. Exp. Ther. 327: 683-691 [PMID: 18787107]

Interaction Information:

Comment Glucose-stimulated insulin release was significantly reduced in islets from obese db/db mice, compared with the control mice. Exendin-4 and valsartan significantly doubled glucose-induced insulin release of db/db isolated islets. A clear synergetic effect was observed with the combination to the extent that these levels were comparable with those in normal m/db islets.
Formal Description
Interaction-ID: 16371

drug/chemical compound


increases_activity of

in pancreas, in pancreatic islets; in db/db mice